Register
Login:
Share:
Email Facebook Twitter


Share Views: Mike van Dulken on today's Company Results and Macro considerations


Sareum Share Chat (SAR)



Share Price: 0.775Bid: 0.75Ask: 0.80Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.05Spread as %: 6.67%Open: 0.775High: 0.775Low: 0.775Yesterday’s Close: 0.775


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Thoth2
Posts: 1,534
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.775
RE: AZN's Mystic cancer drug trial ..
Today 15:45
However dr zed. There are some io drugs that do not work as expected. That tyk2 may resolve. Which john is supposed to be reporting on q2/q3. I have been unable to find the source article so have no idea if this may apply to the azn drug that failed today
 
Thoth2
Posts: 1,534
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.775
RE: AZN's Mystic cancer drug trial ..
Today 15:22
Interestingly. Nsclc was one of the indications when the chk1 trial started. But was not in the redesign srra submitted. Thought it odd. Unless its one of the indications for a combo trial that sierra hasnt given us any info on yet. Except that they are looking at combo trials......
Dr.Zed
Posts: 582
Off Topic
Opinion:No Opinion
Price:0.775
RE: AZN's Mystic cancer drug trial ..
Today 15:10
AstraZeneca, the Anglo-Swedish pharmaceutical company, has suffered a big setback after a much-awaited trial of a new lung cancer drug failed to show the benefits for which the company had hoped.

The study, known as Mystic, features an immunotherapy drug that AZ hopes will eventually be adopted as a first line treatment in preference to chemotherapy, for non-small cell lung cancer. However, results released today show that it did not reach its “endpoints” for progression free survival — the length for which people go without their cancer worsening.

KR

ZA
Kato_rocks
Posts: 2
Observation
Opinion:No Opinion
Price:0.775
AZN's Mystic cancer drug trial fail
Today 14:47
http://www.marketwatch.com/story/astrazenecas-mystic-cancer-drug-trial-fails-2017-07-27

Quote from the above link "AZN combination of two of its new oncology drugs failed to shrink lung cancer tumors in a closely watched clinical trial, casting doubt on a central part of the company's ambitious growth plans."

I don't have the expertise to know but would this make SAR more desirable or increase focus on Sierra / CHK1 ?
boss007
Posts: 850
Observation
Opinion:Strong Buy
Price:0.775
RE: Sierra
Today 10:38
agree about low share price, but they have signed a contract, and we will get a big slice of the cake if this is a blockbuster......this low year price is a worry only if a silly takeover price comes, but am of believe that if this is a blockbuster tyk2 , other companies will not the other take it on the cheap. As Thoth has said, not many TYK2 compounds doing well in clinical studies, ours is kicking the leading licensed drug backside.....patience is key here....been here 8 years......and things have never looked better than now, in terms of two brilliant molecules, for two massive markets......faith
Warthog4
Posts: 502
Observation
Opinion:No Opinion
Price:0.775
RE: Sierra
Today 08:40
That's what I am afraid of as well. I had another druggy share where the company became involved with a big corporation and became completely sideliined with no mention of them in press releases and despite much trumpeted benefits from the involvement nothing ever happened and the SP is still in the doldrums.
rayboy
Posts: 1,680
Off Topic
Opinion:No Opinion
Price:0.775
Just
Today 08:26
Had little £1200 top up
Basser1
Posts: 19
Off Topic
Opinion:No Opinion
Price:0.775
Sierra
Wed 23:51
9% up in two days yet SAR is still held back by strange big sells which had they waited half an hour could have made more profit. Reason - they are interested in the bigger picture - getting SAR on the cheap. The danger is we will not get the value the company deserves.
Utahsaints
Posts: 895
Off Topic
Opinion:No Opinion
Price:0.775
RE: Ok?
Wed 21:39
Sierra could quite easily get to 2 cents by end of week
Thoth2
Posts: 1,534
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.775
RE: Ok?
Wed 21:32
Am in milan doing some work and relax.
Sierra. Its not a blinded trial. So srra will have a good insight whether patients who have failed othrr treatments are responding already.
Lilly is resurecting its chk1 as a combo. But its is i travenous not oral and most of its trials stopped sfter p2. Suggesting tox issues. Unlike ours.
Good luck sierra. And for all our moans about tim. He did make the choices to focus ******* scarce resources at the time. On 2 compunds that look blockbusters. (Which wasnt evident 5 yeats ago). And stole a march. I have more patience than the market as malny of us do. Gla.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.